Assessment Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: Together with chemotherapy, to the cure of Grownup clients with locally recurrent unresectable or metastatic triple-damaging breast most cancers who may have not been given prior chemotherapy for metastatic condition and whose tumours express programmed mobile death-lig